参考文献/References:
［1］王存同，郑晓瑛，陈功．我国已婚育龄人群避孕水平及避孕方法使用趋势 ［J］．人口学刊，2007（4）：57-62．
［2］李玉艳，武俊青．我国口服避孕药的使用现状和对策 ［J］．中国计划生育学杂志，2016，24（8）：508-511．
［3］SCHINDLER A E. Non-contraceptive benefits of oral hormonal contraceptives ［J］. International Journal of Endocrinology and Metabolism, 2013, 11(1): 41-47.
［4］HARLAP S, SHIONO P H, RAMCHARAN S, et al. Chromosomal abnormalities in the Kaiser-Permanente Birth Defects Study,with special reference to contraceptive use around the time of conception ［J］. Teratology, 1985, 31(3): 381-387.
［5］WALLER D K, GALLAWAY M S, TAYLOR L G, et al. Use of oral contraceptives in pregnancy and major structural birth defects in offspring ［J］. Epidemiology, 2010, 21(2): 232-239.
［6］HANNAFORD P C, SELVARAJ S, ELLIOTT A M, et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioners' oral contraception study ［J］. British Medical Journal, 2007, 335(7621): 651-654A.
［7］JATOI A, FOSTER N R, KALLI K R, et al. Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival ［J］. BMC Cancer, 2015, 15(1):1-7.
［8］WHO．Medical eligibility criteria for contraceptive use．A WHO family planning cornerstone ［M］．4th ed．Geneva：WHO．2009．
［9］LUAN Nan-nan, WU Lang, GONG Ting-ting, et al. Nonlinear reduction in risk for colorectal cancer by oral contraceptive use: a meta-analysis of epidemiological studies ［J］. Cancer Causes & Control： CCC, 2015, 26(1): 65-78.
［10］BOSETTI C, BRAVI F, NEGRI E, et al. Oral contraceptives and colorectal cancer risk: a systematic review and meta-analysis ［J］. Human Reproduction Update, 2009, 15(5): 489-498.
［11］DE MELO A S, DOS REIS R M, FERRIANI R A, et al. Hormonal contraception in women with polycystic ovary syndrome: choices, challenges, and noncontraceptive benefits ［J］. Open Access Journal of Contraception, 2017, 8: 13-23.
［12］ZGE Y, TUNCAY Y, AMURDAN M O, et al. Overview of abnormal uterine bleeding in adolescents:diagnosis and management ［J］. International Journal of Womens Health & Reproduction Sciences, 2017, 5(3): 158-163.
［13］Shehata N A. Calcium versus oral contraceptive pills containing drospirenone for the treatment of mild to moderate premenstrual syndrome: a double blind randomized placebo controlled trial ［J］. European Journal of Obstetrics Gynecology & Reproductive Biology, 2016, 198:100-104.
［14］付艺，宓为峰，李玲芝，等．屈螺酮炔雌醇片治疗经前期情绪障碍的疗效及安全性 ［J］．中华妇产科杂志，2014，49（7）：506-509．
［15］复方口服避孕药临床应用中国专家共识专家组．复方口服避孕药临床应用中国专家共识 ［J］．中华妇产科杂志，2015，50（2）：81-91．
［16］WADA-HIRAIKE O, OSUGA Y, HIROI H, et al. Sessile polyps and pedunculated polyps respond differently to oral contraceptives ［J］. Gynecological Endocrinology, 2011, 27(5): 351-355.
［17］武俊青．提问技巧 ［J］．中国计划生育学杂志，2014，22（2）：135-137．
［18］武俊青．语言交流技巧 ［J］．中国计划生育学杂志，2013，21（12）：851-855．
［19］武俊青．非语言交流技巧 ［J］．中国计划生育学杂志，2014，22（1）：65-69, 72．
［20］武俊青．模具教具和图片技巧 ［J］．中国计划生育学杂志，2014，22（3）：207-212．
相似文献/References:
[1]鞠方,雷贞武.目前有关避孕药安全性的争议问题[J].中国计划生育和妇产科,2013,(03):0.
JU Fang,LEI Zhen - wu * ..[J].Chinese Journal of Family Planning & Gynecotokology,2013,(6):0.
[2]李瑛.复方口服避孕药不良反应的处理及预防[J].中国计划生育和妇产科,2018,(6):3.
[3]杨月华.迟服或漏服复方口服避孕药的处理[J].中国计划生育和妇产科,2018,(6):12.